Examinando por Autor "Campoy, Sergio"

Mostrando 1 - 1 de 1
  • Miniatura
    Ítem
    Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
    (BioMed Central Ltd, 2023-06-02) Muñoz-Vendrell, Albert; Campoy, Sergio; Caronna, Edoardo; Alpuente Ruiz, Alicia; Torres Ferrús, Marta; Nieves Castellanos, Candela ; Olivier, M.; Campdelacreu Fumadó, Jaume; Prat, Joan; Camiña Muñiz, J.; Molina Martínez, Francisco José ; Mínguez Olaondo, Ane; Ruibal, M.; Santos Lasaosa, Sonia; Navarro Pérez, María Pilar; Morollón, Noemí ; López Bravo, Alba ; Cano Sánchez, L.M.; García-Sánchez, S.M.; García-Ull, Jesica; Rubio-Flores, Laura.; Gonzalez Martinez, Alicia; Quintas, Sonia ; Echavarría Íñiguez, Ana ; Gil Luque, Sendoa; Castro-Sánchez, M.V.; Adell Ortega, V.; García Alhama, J.; Berrocal-Izquierdo, N.; Belvís Nieto, Roberto; Díaz Insa, Samuel ; Pozo Rosich, Patricia ; Huerta Villanueva, Mariano
    Background: Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods: In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results: A total of 162 patients were included, median age 68 years (range 65–87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.1 ± 7.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days ≥ 30%, ≥ 50%, ≥ 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions: Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice. Graphical Abstract: [Figure not available: see fulltext.]